Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects
- PMID: 28673587
- DOI: 10.1016/j.mehy.2017.05.002
Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects
Abstract
Obesity and diabetes are associated with deficits in multiple neurocognitive domains and increased risk for dementia. Over the last two decades, there has been a significant increase in bariatric and metabolic surgery worldwide, driven by rising intertwined pandemics of obesity and diabetes, along with improvement in surgical techniques. Patients undergoing bariatric surgery achieve a significant decrease in their excess weight and a multitude of sequela associated with obesity, diabetes, and metabolic syndrome. Glucagon-like peptide 1 (GLP-1) is an intestinal peptide that has been implicated as one of the weight loss-independent mechanisms in how bariatric surgery affects type 2 diabetes. GLP-1 improves insulin secretion, inhibits apoptosis and induce pancreatic islet neogenesis, promotes satiety, and can regulate heart rate and blood pressure. Moreover, numerous studies have demonstrated potential neuroprotective and neurotrophic effects of GLP-1. Increased GLP-1 activity has been shown to increase cortical activity, promote neuronal growth, and inhibit neuronal degeneration. Specifically, in experimental studies on Alzheimer's disease, GLP-1 decreases amyloid deposition and neurofibrillary tangles. Furthermore, recent studies have also suggested that GLP-1 based therapies, new class of antidiabetic drugs, have favorable effects on neurodegenerative disorders such as Alzheimer's disease. We present a hypothesis that bariatric surgery can help delay or even prevent the onset of Alzheimer's disease in long-term by increasing the levels of GLP-1. This hypothesis has a potential for many studies from basic science projects to large population studies to fully understand the neurological and cognitive consequences of bariatric surgery and associated rise in GLP-1.
Keywords: Alzheimer’s disease; Bariatric surgery; Dementia; Diabetes; Gastric bypass; Glucagon-like peptide 1; Insulin; Metabolic surgery; Obesity; Weight loss.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery.Diabetes Metab. 2009 Dec;35(6 Pt 2):518-23. doi: 10.1016/S1262-3636(09)73459-7. Diabetes Metab. 2009. PMID: 20152737 Review.
-
How to fight obesity with antidiabetic drugs: targeting gut or kidney?Minerva Endocrinol. 2015 Mar;40(1):71-83. Epub 2014 Nov 4. Minerva Endocrinol. 2015. PMID: 25366984 Review.
-
Neuro-modulation and bariatric surgery for type 2 diabetes mellitus.Int J Clin Pract Suppl. 2010 Feb;(166):53-8. doi: 10.1111/j.1742-1241.2009.02279.x. Int J Clin Pract Suppl. 2010. PMID: 20377665 Review.
-
Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives.Diabetes Metab. 2009 Dec;35(6 Pt 2):537-43. doi: 10.1016/S1262-3636(09)73463-9. Diabetes Metab. 2009. PMID: 20152741 Review.
-
[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].Rev Neurol. 2014 Dec 1;59(11):517-24. Rev Neurol. 2014. PMID: 25418147 Review. Spanish.
Cited by
-
The changes in cognitive function following bariatric surgery considering the function of gut microbiome.Obes Pillars. 2022 May 18;3:100020. doi: 10.1016/j.obpill.2022.100020. eCollection 2022 Sep. Obes Pillars. 2022. PMID: 37990721 Free PMC article. Review.
-
Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023. Front Aging Neurosci. 2023. PMID: 36845652 Free PMC article. Review.
-
Development of dementia in patients who underwent bariatric surgery.Surg Endosc. 2023 May;37(5):3507-3521. doi: 10.1007/s00464-022-09837-z. Epub 2022 Dec 29. Surg Endosc. 2023. PMID: 36581785
-
Sleeve Gastrectomy Reduces Glycemia but Does Not Affect Cognitive Impairment in Lean 5xFAD Mice.Front Neurosci. 2022 Aug 11;16:937663. doi: 10.3389/fnins.2022.937663. eCollection 2022. Front Neurosci. 2022. PMID: 36033613 Free PMC article.
-
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus.Front Neurosci. 2021 Aug 11;15:708547. doi: 10.3389/fnins.2021.708547. eCollection 2021. Front Neurosci. 2021. PMID: 34489627 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
